Neoadjuvant Oncolytic Virus OrienX010 Combined with PD-1 Inhibitor Toripalimab for Resectable Acral Melanoma: Phase Ib Clinical Trial Background Acral melanoma (AM) is a highly aggressive subtype of melanoma with a high incidence in the Chinese population, accounting for approximately 40% of melanoma cases. Despite advances in melanoma treatment, c...

Research Report on Efferocytosis Features and Their Prognostic and Immunotherapy Associations in Lung Adenocarcinoma Background and Research Motivation Lung cancer is a leading cause of cancer-related mortality worldwide, with lung adenocarcinoma (LUAD) being the most common histological subtype. Due to the insidious nature of the disease and lack ...

Tumor Analysis of BRCA1/2 Carriers: Genomic Similarities Evident Across Different Time Points Breast cancer (BC) is the most common malignant tumor among women globally, with its pathogenesis predominantly sporadic, while familial hereditary cases account for only 5% to 10%. Among various pathogenic molecules, mutations in the BRCA1/2 genes (Pathog...

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: A Multicenter, Retrospective Real-World Study Background and Research Motivation Multiple sclerosis (MS) is a chronic, complex, inflammatory, and degenerative demyelinating disease primarily affecting the central nervous system (CNS). It can lead to neurological impairments in ...

Optimized Nutritional Interventions Improve Muscle Fatigue, Strength, and Quality of Life in Patients with Primary Mitochondrial Disease Background Introduction Primary mitochondrial disease (PMD) encompasses a group of disorders caused by mutations in mitochondrial DNA or nuclear DNA, affecting systemic energy metabolism. The prevalence is approxi...